TRT Jatenzo denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for trt jatenzo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Jatenzo on Medical-Necessity Grounds

Aetna's medical-necessity denial on Jatenzo (oral testosterone undecanoate) means the documentation submitted at the time of the prior-authorization request did not satisfy Aetna's published clinical criteria for testosterone replacement therapy or for this specific oral formulation. Aetna's coverage policies for testosterone products typically require documented diagnosis, symptom burden, and — in some policies — a rationale for why the specific formulation requested is appropriate over other options. A medical-necessity denial is one of the most commonly appealed and overturned denial types.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of the denial. Aetna must respond within 30 days for standard reviews and 72 hours for expedited.
• External review: After a final internal denial, escalate to an independent review organization within approximately four months. The IRO's decision is binding on the plan.
• Expedited track: Request expedited review if delay would seriously jeopardize health.

## Why Jatenzo Specifically Requires a Formulation Rationale

Jatenzo is an oral testosterone product, which is a distinct formulation from injectable or topical alternatives. Aetna's medical-necessity criteria may require an explanation of why oral administration is clinically indicated for this patient, particularly given that oral testosterone products have a different absorption and monitoring profile than other formulations. Your appeal should address this directly through the prescriber's letter, with reference to the FDA-approved prescribing information.

## What to Gather

1. Confirmed hypogonadism diagnosis — lab reports with clinician interpretation and a clear diagnosis code consistent with the FDA-approved indication. 2. Symptom documentation — office notes describing the nature and functional impact of symptoms (fatigue, sexual dysfunction, mood, physical changes) over time. 3. Prescriber medical-necessity letter — explains why Jatenzo is clinically appropriate for this patient, why oral administration is the appropriate route, and how the patient's clinical profile aligns with Aetna's coverage criteria and the FDA-approved indication. 4. Prior-treatment history — records of any prior testosterone therapy (including formulation, dates, duration, and outcomes), if applicable to Aetna's criteria. 5. Applicable guideline reference — generic citation to the Endocrine Society guideline on male hypogonadism, without specific numeric thresholds.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy bulletin for testosterone replacement therapy. Build a response table:

| Aetna Policy Requirement | Supporting Evidence | |---|---| | Confirmed diagnosis of hypogonadism | Lab report [date], diagnosis note | | Documented symptomatic presentation | Office note [date], symptom list | | Appropriate formulation rationale | Prescriber letter — oral route justification | | Prior therapy history (if required by policy) | Prior-treatment records |

Request a peer-to-peer review between your prescriber and Aetna's medical director — this step is particularly effective when the clinical rationale is detailed and the prescriber can speak directly to the formulation-specific medical reasoning.